While MTD AT/DT (IV) did not significantly alter T cell populations, oral MCT AT/DT-NE#E—particularly in combination with anti-PD1—significantly increased tumor-infiltrating CD45+, CD4+, and CD8+ T cells, and T cell activation in TDLNs. Here, PDCD1 is linked to neoplasm.